Follow-The-Filings

Security · featured owners

URGN Urogen Pharma Ltd

COM Equity as of 2026 Q2 among managers we track

  • 4 Owners
  • Max 4.8%
  • $59M
  • 1 new 1 add 1 reduce 1 exit

Who owns this now

Largest portfolio weights among featured holders · max 4.8% (James Silverman - Opaleye...) · not free-float ownership

  1. James Silverman add 4.8%
  2. Palo Alto Investors 0.12%
  3. Cathie Wood reduce 0.02%
  4. Polen Capital Management new 0.01%

holders

sorted by value · long equity only · current book 2026 Q2 · exits show last held size · open a manager for their book

history
James Silverman - Opaleye Management 2026 Q2 4.8% Add +0.7% 1,439,996 $53M history
Cathie Wood - Ark Investment Management 2026 Q2 0.02% Reduce −12.1% 101,508 $4M history
Polen Capital Management 2026 Q2 0.01% New 0.01% 29,615 $1M history
Palo Alto Investors 2026 Q2 0.12% Hold 24,500 $902K history
Farallon Capital Management exited 2026 Q2 last 2026 Q1 <0.01% Exit 0.00 pp 11,000 $198K history

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $82.71M $90.4M $109.79M
Gross profit $73.35M $81.52M $97.34M
Gross margin * 88.7% 90.2% 88.7%
Net income -$102.24M -$126.87M -$153.49M
Net margin * -123.6% -140.4% -139.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $169.19M $276.14M $186.02M
Total non-current assets * $9.12M $9.58M $14.43M
Total assets $178.31M $285.71M $200.46M
Total current liabilities $31.21M $45.95M $46.42M
Total non-current liabilities * $212.31M $248.56M $259.51M
Total equity -$65.21M -$8.8M -$105.47M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$76.38M -$96.77M -$162.44M
Cash from investing -$953,000 -$20.61M $61.56M
Cash from financing $116.93M $194.62M $39.92M
Net change in cash $39.6M $77.24M -$60.97M

ownership over time

filing count by report period · click a bar for that quarter’s holders